Background: The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or timeto-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition † Results: Recommended guidelines for the definition of TTE end points commonly used in RCT for sarcomas and GIST are provided for adjuvant and metastatic settings, including DFS, TTF, time to progression and others.
of time-to-event (TTE) end points is rarely precise and lacks uniformity across trials. End point definition can impact trial results by affecting estimation of treatment effect and statistical power. The DATECAN initiative (Definition for the Assessment of Time-to-event End points in CANcer trials) aims to provide recommendations for definitions of TTE end points. We report guidelines for RCT in sarcomas and gastrointestinal stromal tumors (GIST).
Methods:
We first carried out a literature review to identify TTE end points ( primary or secondary) reported in publications of RCT. An international multidisciplinary panel of experts proposed recommendations for the definitions of these end points. Recommendations were developed through a validated consensus method formalizing the degree of agreement among experts.
introduction In randomized clinical trial (RCT) in cancer, the validated and most objectively defined evaluation criterion is overall survival (OS), defined as the time interval between randomization and death (all causes). Therapeutic progress, which in certain contexts has significantly reduced mortality, the development of new types of cytostatic drugs as well as the multiplication of lines of treatment have resulted in the need for end points that measure efficacy with precision and that are available earlier than OS. Such alternative composite time-to-event (TTE) end points include for example progression-free survival (PFS) in second-line treatment. These potential surrogate end points are increasingly being used to replace OS [1] and their development is strongly influenced by the goal to reduce the number of patients in clinical trials, the duration and ultimately the cost of RCT.
As recommended by the International Conference on Harmonisation (ICH) guidelines [2] and the CONSORT statement [3] , each TTE end point should be precisely defined. This implies specifying the date of origin, the list of events to be considered as failures and the censoring process. In addition, we expect that, for a given disease and setting, each TTE end point should encompass the same set of events across trials. However, most TTE end points are often poorly defined, and when a definition is provided, it can vary between publications, as underlined by recent works [4, 5] and by the Food and Drug Administration [6] . For illustration, Mathoulin-Pélissier et al.
showed that a precise definition of TTE end points was reported for only 52% of cancer RCT published in major journals [4] . Toulmonde et al. showed that clear definitions of primary and secondary outcome measures were reported in only 33% of published RCT reporting on the treatment of sarcomas [5] . Similar results have been highlighted for phase II sarcoma trials [7] .
The heterogeneity of TTE end point definitions has been highlighted by the international community, as demonstrated by recent publications recommending the definition of specific criteria and/or the preferred use of certain criteria in specific localizations such as for colorectal cancer [8] , hepatocellular carcinoma [9] , breast cancer [10] or lymphoma [11] . Most of these recommendations were based on experts' opinions, without a formal international consensus process, which could explain why some have not yet been widely adopted in practice. To our knowledge, no definition of TTE end points has yet been proposed for sarcomas and gastrointestinal stromal tumors (GIST). This lack of standardized definitions clearly constitutes a limitation to the use of alternative TTE end points as efficacy end points.
It is important to distinguish between the process of selecting the relevant end point and the process of defining this end point. The selection of TTE end points to assess a therapeutic strategy will depend on the characteristics of the trial including settings (adjuvant versus metastatic) and treatments (systemic, local or any combination thereof ). As such, the choice of the primary end point will be trial-specific. On the other hand, once the end point is identified, it has to be appropriately defined, ideally using a standardized definition to ensure future comparisons.
Based on a formal consensus process, we developed the international DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) [12] , which aims to obtain standardized consensus definitions for multiple cancer sites: sarcomas/GIST, pancreas, breast, stomach/esophagus, head and neck, colon/rectum, kidney/bladder and lung cancers. Here, we report guidelines for the definitions of TTE end points used in cancer RCT in sarcoma and GIST treatment.
methods
The DATECAN project was initially launched in 2010 for three cancer sites: sarcoma/GIST, pancreatic and breast cancers. The coordinating committee (CC) for sarcoma and GIST included three experts (CB, SMP, MO). In addition to the CC members, the steering committee included sarcoma/GIST experts in medical oncology (NP, PC), radiation oncology (OSN, MD) and surgery (SB). An independent group of experts, the rating committee (RC), was in charge of scoring the questionnaires.
consensus process
A formal consensus method was used to develop these guidelines [13, 14] . We relied on a modified Delphi consensus method and limited ourselves to two rounds of questionnaires with a final in-person meeting to discuss items for which consensus has not been reached after two rounds of rating. The purpose of the formal consensus method is to formalize the degree of agreement among experts, using iterative ratings with feedback to identify and select points on which there is disagreement or uncertainty. The guidelines are subsequently based on agreement scores. The formal consensus method involves the following steps ( Figure 1 ): (i) assessment of the evidence with regard to the research question; (ii) elaboration and pretesting of the questionnaire to collect experts' opinions; (iii) scoring of the questionnaires; (iv) analysis of the experts' opinions and drafting of the final report; (V) peer review phase; (vi) diffusion of the recommendations. An overview of these steps is provided in supplementary Data S1, available at Annals of Oncology online. We refer the reader to an earlier publication for a full description of the methodology of the consensus process [12] .
literature reviews
We conducted literature reviews (i) to assess whether guidelines had been previously developed for TTE end points used in trials for the treatment of sarcomas and GIST and (ii) to list TTE end points commonly reported, either as primary or secondary end points. The used research algorithms are available in supplementary Data S2, available at Annals of Oncology online.
questionnaires
In the first round, all experts of the RC received the same questionnaire (one for sarcoma, one for GIST) to score each TTE end point on a scale of 1 (totally disagree) to 9 (totally agree), according to whether various clinical events should be regarded as events in the definition of TTE outcomes. In the second round, each expert of the RC received a personalized questionnaire (supplementary Data S3, available at Annals of Oncology online). Items for which strong consensus had been reached after the first round were highlighted. For items without consensus, the distributions of scores obtained at the first round were summarized (minimum, maximum and median scores), and the initial score of the RC expert was indicated. Experts were asked to rescore items for which consensus had not been reached. By construction, results selection of TTE end points to be defined and clinical events of interest
We identified 14 TTE end points from the literature review and established a list of clinical events that could be included in the definition of these end points (Table 1) .
experts for the scoring process
The CC drafted a list of 57 experts for the RC. Of the 32 experts who filled in the first questionnaire, 28 (87%) also participated in the second round of rating. The 28 experts (supplementary Data S4-S6, available at Annals of Oncology online) were specialists in medical oncology (n = 14; 50%), radiation oncology (n = 3; 11%), surgery (n = 7; 25%), epidemiology/biostatistics (n = 3, 11%) and pathology (n = 1, 3% consensus rates after the two rounds of rating
The consensus process involved two rounds of rating (first round: November 2010 to November 2011; second round March 2012 to May 2012) and one face-to-face meeting (3 June 2012, Chicago, IL). In the sarcoma questionnaire, overall, experts rated a total of 224 events pertaining to the 14 TTE end points. The same number of events had to be rated for GIST, leading to a total of 448 events. The scoring process is summarized in Supplementary Data S1 (available at Annals of Oncology online). After the first round, strong consensus was reached for 37 (8%) of the events. After the second round, strong consensus was reached for 306 events (68%), and strong or relative consensus was reached for 327 events (73%).
face-to-face meeting
After the rating process, strong consensus was not reached for 142 events covering all 14 end points for sarcomas and GIST. Discussion was therefore needed for these events and took place during the face-to-face meeting. Before discussing each event on an individual basis, and with the aim of harmonization, experts present at the meeting first made a number of decisions. The aim of this preliminary discussion was fourfold: to select the items that would be discussed, to maintain the consensus process even though not all experts attended the meeting and were therefore unavailable for discussion, to decide on the procedure to adopt in case of absence of consensus and to attempt to adopt homogeneous rules for sarcomas and for GIST. A summary of these preliminary decisions is available online (supplementary Data S7, available at Annals of Oncology online).
standardized definitions of TTE end points Table 2 summarizes the events to be included in the definition of each TTE end point following the consensus process with a longer version available online (supplementary Data S8, available at Annals of Oncology online). Of the 14 end points initially proposed, 2 were considered ambiguous and/or redundant with other end points (failure-free survival (FFS), and relapse-free survival, RFS). As such, experts discouraged their use. Common definitions were adopted for sarcomas and GIST. The reference date is usually the date of randomization, but it can also be the date of diagnosis or treatment initiation depending on the study. End points were defined according to the setting. Two end points were specifically defined for the adjuvant setting (or disease no longer detectable): disease-free survival (DFS) and (distant) metastasis-free survival. For the metastatic setting, the following end points were defined: PFS, local progression-free survival and metastatic progression-free survival. Finally, definitions were provided for end points that can be used in any setting: disease-specific survival, locoregional relapse-free survival, time to progression (TTP), time-to-local progression, time-to-locoregional progression, time-to-distant progression, time-to-treatment failure.
validation of the guidelines and peer review
Minutes of the in-person meeting which included the final guidelines were validated by email by all participating experts of the RC and next submitted to a peer review group for external review who provided a formal and advisory opinion on the content and form of the initial version of the guidelines (supplementary Data S4, available at Annals of Oncology online).
discussion
We propose guidelines for the definitions of TTE end points to be used in RCT evaluating treatments on sarcomas and GIST. Following the first round of rating which included 28 international experts from various medical specialties, strong consensus was reached for only 8% of the items and strong or relative consensus was reached for 12%. This lack of initial consensus highlighted the disparity of experts' opinions and the need for harmonization. These consensus rates improved to 68% (strong consensus) and 73% (strong or relative consensus) at the second round. The primary reason for observing an improvement in the consensus rates is related to the design of the consensus process. By construction, the formal consensus process aims to guide experts to take position, while allowing them to maintain their opinion at each scoring round. Another reason for explaining such improvement is the different rules used to define consensus after each round. Rules for the second round are slightly relaxed to ensure that the systematic exclusion of a proposal by a rater blocks the consensus process [12, 13] . Questionnaires did not make the distinction between adjuvant and metastatic settings. Yet, this absence of distinction between settings cannot explain entirely the divergence of opinions between experts. Indeed, although the strong consensus rate was extremely low at the first round (8%), it went up to 68% at the second round without adding any specification of the setting, suggesting that absence of specification of the setting was not responsible for the low consensus rate observed initially. Discussion of the setting was introduced at the meeting which allowed to distinguish those items to be used in one specific setting or in both, and thus to provide more concise definitions. For example PFS should be preferred for metastatic settings, while DFS should be kept for adjuvant situations only.
The consensus process underlined that two end points were not particularly relevant, either because of redundancy or ambiguity. Results of the second rating round suggested that the same events should be included for RFS (defined for all settings), DFS (defined for the adjuvant setting) and PFS (defined for the metastatic setting). To reduce ambiguity and to ensure precision, experts proposed not to use the TTE end point RFS, but instead rely on DFS and PFS, respectively, for the adjuvant and metastatic settings.
FFS was also subject to debate. Specifically, following the second round of rating, there was no consensus for the inclusion of second cancers, and experts did not reach a consensus at the meeting either. Other events to be included in FFS were similar to those included in the definition of DFS and PFS. As a result, it was judged that this TTE end point did not add any relevant information and should not be used as an end point in RCT.
Finally, disease-specific survival (DSS) was initially named cancer-specific survival. Since no consensus was reached after the two scoring rounds, experts at the meeting considered that this term was ambiguous and propose to change it to DSS.
Our initial list of TTE end points was established following a literature review of recent randomized trials. The review highlighted that a majority of RCT for sarcomas and GIST assessed two or more TTE end points, usually OS, and either PFS, DFS or TTP, as also discussed in recent reviews [15, 16] . Although not all of the 12 end points defined in these guidelines are used on a frequent basis, they can be relevant (as primary or secondary end points) in specific trials depending on the setting and treatment investigated. Our objective was to propose a large panel of definitions, so that researchers can find a standardized definition for the outcome that best suits the objective of their study.
The initial literature review also showed that the generic term, event-free survival (EFS), was commonly used but could have multiple definitions [17] [18] [19] [20] [21] [22] [23] . For illustration, in a trial of children with osteosarcoma without clinically detectable disease, EFS was defined as the time from study entry until adverse event or last patient contact, whichever came first [18] . Adverse events included disease progression, diagnosis of second malignant neoplasm, or death before disease progression. On the other hand, EFS included relapse after complete response, death from any cause, and nonresponse (taken as date of change to 'off-protocol' therapy) in a trial of nonmetastatic rhabdomyosarcoma in children [17] . Again, this reflects the need for concise and precise definitions of TTE end points. We can also wonder if the use of alternative definitions for a same outcome could have affected the conclusions of these trials, since it has been shown that different definitions can lead to different trial conclusion, as highlighted for colorectal and breast cancer [24, 25] .
We have provided some general guidance for defining multiple TTE end points; nevertheless, some of them have to be refined according to the clinical setting. For example in the case of retroperitoneal sarcoma, when we evaluate the role of perioperative radiotherapy based on locoregional relapse-free survival, it must be precisely defined if peritoneal lymph nodes or liver metastases are part of locoregional relapse. This example illustrates the importance of the dialog between clinicians and statisticians when designing clinical trials.
Similarly, several tools are available to measure progression and/or relapse (e.g. RECIST [26] or Choi criteria [27] ). It is however important to distinguish between the 'concept' and the 'measures', that is, between, 'which' outcomes to measures and 'how' to measure them. Both are crucial when designing trials, but complex enough so that they could not be addressed at once in this work. Measurement tools (but also the calendar of surveillance, imaging techniques etc.) must be defined study by study while accounting for the evolution of the conceptual elements to be included in the definitions of the end points. Just as the development of standardized definitions, these issues could be addressed with consensus processes using independently different trials' scenarios (disease, setting, treatment).
We deliberately did not include recommendations about the censoring process. When a clinical event is not included in a definition, it can be censored, ignored or accounted for (using competing-risk analysis) in the statistical analysis and the selected method will be study-specific depending on objectives (Additional discussion in supplementary Data S9, available at Annals of Oncology online).
Using composite TTE end points requires that the specific events be collected during patients' follow-up. When designing the trial, this implies clearly defining the TTE end points used as primary and secondary end points, the events that constitute these end points, the schedule and duration of patient follow-up as well as the tools to measure these events (e.g. RECIST [26] or Choi criteria [27] ). Since an end point is constituted by several events, it is important that events beyond the first one observed be collected. For example assuming PFS is the primary end point, local progression can preclude distant progression, but only the date of the local progression will be used for the estimation of PFS. Patient follow-up and data collection beyond local progression can provide complementary information with regards to treatment effect on distant progression. Hudis et al. provide an extensive discussion on this issue of follow-up and data collection [10] and emphasize that patient follow-up and data collection should go beyond the occurrence of the first event. Similarly, the cause of death and the site of first metastatic progression should be collected, including their timing. When reporting study results, a breakdown of the type of events that constitute each TTE end point in addition to the usual estimated median survival time should be reported whenever possible.
Finally, formal consensus techniques are recognized methods for developing core outcome sets to measure in clinical trials [28] . The formal consensus methodology and the participation of international experts should increase the validity and the utility of these guidelines, and as such should contribute to the generalizability and the acceptability of the resulting recommendations and their wide-scale implementation in future research.
conclusion
The formal consensus process was used to elaborate standardized definitions of TTE end points in RCT for sarcomas and GIST. The availability of these guidelines should improve international comparisons of trials' results. These recommendations could be disseminated for acquisition and endorsement by researchers and academic groups participating in clinical research. In addition, such guidelines could be of interest to other potential users including reviewers and editors of scientific journals which have recently shown increased interest in the quality of reporting clinical trials [4, 5, 29] , regulatory authorities [6] or any research scientist or initiative interested in improving outcome measurements and reporting of clinical trials [30] . We therefore emphasize that it is particularly important to collect and publish detailed data on those distinct clinical events that contribute to these TTE end points, including events that follow occurrence of a first event.
Future perspectives of the DATECAN project and ongoing work include extensions to additional cancer sites (breast cancer, pancreatic cancer, stomach/esophagus, kidney, bladder, head and neck, colon, lung cancers), assessment of the impact of these definitions on academic cancer RCT as well as evaluation of the statistical properties of the newly defined intermediate end points (in particular PFS and DFS) as surrogates for OS. This ongoing work should inform us on the performance of these end points to adequately capture treatment effect depending on the disease, setting (adjuvant, metastatic) and treatment (local, cytotoxic, cytostatic etc.).
